View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 6, 2017updated 01 Dec 2021 12:38pm

Novartis to in-licence ECF843 for ophthalmic indications globally

Swiss pharmaceutical company Novartis has exercised an option to in-licence ECF843 for ophthalmic indications worldwide (outside Europe), as part of efforts to strengthen its R&D pipeline.

Swiss pharmaceutical company Novartis has exercised an option to in-licence ECF843 for ophthalmic indications across worldwide (outside Europe), as part of efforts to strengthen its R&D pipeline.

With this in-licensing, Novartis will be able to build up its experience in ophthalmology and dry eye treatments with a global portfolio of artificial tear products that include Systane, Tears Naturale and Genteal.

Developed by US-based Lubris, ECF843 is a recombinant form of human lubricin (rh-Lubricin) protein. Lubricin is an endogenous glycoprotein expressed in areas of high shear stress and friction, including the tear film.

The protein deficiency is observed in dry eye patients.

Novartis global head of drug development and chief medical officer Vasant Narasimhan said: “ECF843 has the potential to be the first therapeutic to provide rapid relief of dry eye symptoms and significantly improve signs.

“Exercising our option to in-licence ECF843, along with our recent acquisition of Encore Medical for the treatment of presbyopia underscores our commitment to treating diseases of the front of the eye, which impact millions of people worldwide.”

“ECF843 has the potential to be the first therapeutic to provide rapid relief of dry eye symptoms and significantly improve signs.”

ECF843 is a new therapeutic approach and a potential Rx treatment in dry-eye, an area of high unmet medical need that impacts more than 344 million patients worldwide.

It is hypothesised to restore the tear film function, reduce friction and also relieve the signs and symptoms of dry eye.

Novartis combined its retina medicines business with the Alcon pharmaceuticals business last year.

The business is currently operating as one ophthalmology franchise under Novartis Pharmaceuticals.


Image: Novartis headquarters in Basel, Switzerland. Photo: courtesy of –Andrew- from Flickr.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology